Business
Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting
BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that data from its rare disease programs will be delivered in three presentations at the American Epilepsy Society 2021 Annual Meeting, held December 3-7, 2021 in Chicago. “We look forward to presenting data at AES on our small molecule rare disease programs, including PRAX-562, a persistent sodium channel blocker, and our KCNT1 inhibitor,” said Steven Petrou, Ph.D., chief scientific officer and co-founder of Praxis. “We are proud to have built a broad pipeline of small molecule and antisense rare epilepsy programs, including PRAX-562 and our lead ASO, PRAX-222, which are both expected to begin first-in-patient trials in the coming months. As these programs have advanced, our portfolio of differentiated treatment approaches for rare epilepsies with significant unmet need has expanded and progressed. We expect to declare a development candidate for the KCNT1 program in the coming months and, through our antisense collaboration with the Florey Institute of Neuroscience and Mental Health in Australia, we are excited to continue research efforts into epilepsies caused by mutations in SCN2A, SYNGAP1, PCDH19 and additional targets currently under evaluation.” Presentation Details: PRAX-562 is a Well-Tolerated Novel Persistent Sodium Current Blocker with Potent Anticonvulsant Activity in Models of SCN2A and SCN8A Gain of Function Epilepsy Session Date/Time: December 4 at 12:00 p.m. CTPresenter: Liam Scott, M.S., Senior Scientist, Translational Sciences, Praxis Precision MedicinesAbstract Number: 1.268 PRAX-562: A Novel Sodium Channel Inhibitor with Greater Potency and Selectivity for Persistent Sodium Current Compared to Standard of Care Session Date/Time: December 5 at 12:00 p.m. CTPresenter: Kris Kahlig, Ph.D., Director, Discovery Sciences, Praxis Precision MedicinesAbstract Number: 2.241 PRX-2904 Is a Small Molecule Selective Inhibitor of KNa1.1 (KCNT1) That Reverses the ECoG Phenotype of a KCNT1 Gain-of-Function Mouse Model Session Date/Time: December 5 at 12:00 p.m. CTPresenter: Archana Jha, Ph.D., Senior Scientist, Discovery Sciences, Praxis ...